Looks at GLP-1 diabetes and obesity drugs in people with pancreatic cysts
Reviews past records of adults with pancreatic cysts who took GLP-1 drugs.
Plain-language title generated from the registry record
Registry title: Impact of GLP-1 Receptor Agonists on Patients With IPMN
Key facts
- Where
- Villars-sur-Glâne, SwitzerlandSee the site
Where in Switzerland
- HFR Hopital fribourgeoisVillars-sur-Glâne, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hôpital Fribourgeois
- Trial code
- NCT07014709
- Record updated
- 11 June 2025
- Original description
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear.Read full original descriptionShow less
Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear.
The study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention
Inclusion: > 18 years old; Radiological diagnosis of IPMN; Treated with GLP-1 RAs; Patients must have provided prior informed consent for the use of their coded clinical data in research.
Exclusion: no documented history of GLP-1 RAs use; radiological diagnosis of IPMN is unclear,; patients did not provide signed informed consent, or have documented refusal for research.